Carboxyamidotriazole Orotate
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Carboxyamidotriazole Orotate, covering 2025-09-09 to 2025-09-09. Get the full timeline:
Most recent: Clinical Trial Update: Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas [Phase 1]